GlassScriptPhysician profile
Joseph Schirripa
NPI 1609804384
$4,143.45
in general payments reported to CMS, 2019-2025
26 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $747 · 2020: $341 · 2021: $576 · 2022: $440 · 2023: $696 · 2024: $898 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,037 · Education: $2.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,037.13 |
| Education | $2.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,163.65 | 2019-2025 | Farxiga, Lokelma |
| Vifor Pharma, INC. | $687.98 | 2019-2025 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $411.83 | 2019-2024 | Jynarque |
| Glaxosmithkline, LLC. | $245.80 | 2022-2024 | Benlysta, Jesduvroq |
| Ardelyx, INC. | $243.34 | 2023-2025 | Ibsrela |
| Daiichi Sankyo INC. | $217.40 | 2019-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $202.26 | 2021-2025 | |
| W. L. Gore & Associates, INC. | $142.73 | 2019 | |
| Novartis Pharmaceuticals Corporation | $111.14 | 2019-2025 | |
| Lilly USA, LLC | $85.28 | 2024-2025 | Jardiance |
| Amgen INC. | $81.22 | 2024-2025 | Tavneos, Krystexxa |
| Fresenius USA Marketing, INC. | $70.07 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.47 | 2023-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $59.55 | 2021-2022 | |
| Opko Pharmaceuticals, LLC | $59.28 | 2019-2025 | Rayaldee |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $53.71 | 2019-2023 | Jynarque |
| Calliditas Therapeutics US INC. | $52.88 | 2022-2025 | Tarpeyo |
| Akebia Therapeutics INC | $38.10 | 2019-2020 | |
| Apellis Pharmaceuticals, INC. | $23.91 | 2025 | |
| Genzyme Corporation | $23.21 | 2023 | |
| Scpharmaceuticals INC. | $21.47 | 2025 | |
| Travere Therapeutics, INC. | $20.34 | 2025 | Filspari |
| Ascendis Pharma Endocrinology INC | $17.71 | 2025 | Yorvipath |
| Novo Nordisk INC | $15.70 | 2024 | Rybelsus, Ozempic |
| Mallinckrodt Enterprises LLC | $14.52 | 2019 | |
| Corcept Therapeutics | $13.90 | 2024 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Schirripa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.